Results 221 to 230 of about 5,542 (243)

Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study

Lancet, The, 2019
Beyong Duk Ye, Adi Lahat, Sigal Fishman
exaly  

Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima

Gut, 2016
Shomron Ben Horin, Itai Benhar, B Ungar
exaly  

Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study

Annals of the Rheumatic Diseases, 2017
Dae-Hyun Yoo, Piotr Wiland, Carlos Abud-Mendoza   +2 more
exaly  

A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry

Annals of the Rheumatic Diseases, 2017
Bente Glintborg, Anne Gitte Loft, Oliver Hendricks   +2 more
exaly  

PHARMACEUTICALS Merck deal with South Korea’s Hanwha bolsters move into biosimilars

Chemical & Engineering News Archive, 2011
openaire   +1 more source

Economics as a guide to developing public policies for biosimilar pharmaceutical products

Queen Mary Journal of Intellectual Property, 2012
openaire   +1 more source

Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial

The Lancet Gastroenterology and Hepatology, 2018
Anne S Strik, M T Nurmohamed, Peter Bossuyt   +2 more
exaly  

Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study

Annals of the Rheumatic Diseases, 2017
Stanley B Cohen, Mark C Genovese, Ernest H Choy   +2 more
exaly  

To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry

Annals of the Rheumatic Diseases, 2019
Bente Glintborg, Anne Gitte Loft, Oliver Hendricks   +2 more
exaly  

Postmarket policy considerations for biosimilar oncology drugs

Lancet Oncology, The, 2016
Matthew J Renwick, Kate Smolina, Emilie J Gladstone   +2 more
exaly